- $4.24bn
- $2.49bn
- 48
- 44
- 38
- 39
Annual cashflow statement for Vaxcyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -89.2 | -100 | -223 | -402 | -464 |
| Depreciation | |||||
| Non-Cash Items | 5.91 | 13.9 | 37.6 | 21 | 59.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 35.3 | -37 | 12.7 | 81.3 | -54.9 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -46.6 | -121 | -171 | -297 | -453 |
| Capital Expenditures | -1.16 | -6.55 | -5.85 | -67.9 | -119 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.05 | -206 | 80.4 | -705 | -1,887 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.1 | -212 | 74.6 | -773 | -2,006 |
| Financing Cash Flow Items | -3.37 | 0 | -0.861 | -3.88 | -14.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 375 | 17.8 | 862 | 640 | 2,449 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 327 | -316 | 766 | -437 | -9.36 |